Rosiglitazone Suppresses Renal Crystal Deposition by Ameliorating Tubular Injury Resulted from Oxidative Stress and Inflammatory Response via Promoting the Nrf2/HO-1 Pathway and Shifting Macrophage Polarization

Table 1

Primers.

Primer (human)	Forward (5-3)	Reverse (5-3)
Ccl2	AGAATCACCAGCAGCAAGTGTCC	TCCTGAACCCACTTCTGCTTGG
CD11c	GATGCTCAGAGATACTTCACGGC	CCACACCATCACTTCTGCGTTC
iNOS	GCTCTACACCTCCAATGTGACC	CTGCCGAGATTTGAGCCTCATG
IL-6	GCACTGGCAGAAAACAACCT	TCAAACTCCAAAAGACCAGTGA
NF-κB	TGAACCGAAACTCTGGCAGCTG	CATCAGCTTGCGAAAAGGAGCC
TNF-α	CCCAGGGACCTCTCTCTAATC	ATGGGCTACAGGCTTGTCACT
CD206	CCGTATGCCGGTCACTGTTA	CAATTCCTCGATGGTGTGGA
Arg1	GTGGAAACTTGCATGGACAAC	AATCCTGGCACATCGGGAATC
IL-4	ATGGGTCTCACCTCCCAACT	GATGTCTGTTACGGTCAACTCG
IL-10	GACTTTAAGGGTTACCTGGGTTG	TCACATGCGCCTTGATGTCTG
IL-1β	ACGCTCCGGGACTCACAGCA	TGAGGCCCAAGGCCACAGGT
Nrf2	CACATCCAGTCAGAAACCAGTGG	GGAATGTCTGCGCCAAAAGCTG
HO-1	CCAGGCAGAGAATGCTGAGTTC	AAGACTGGGCTCTCCTTGTTGC
SOD1	CTCACTCTCAGGAGACCATTGC	CCACAAGCCAAACGACTTCCAG
PPARγ	CATGGCAATTGAATGTCGTGTC	CCGGAAGAAACCCTTGCAT
GAPDH	GACCTGACCTGCCGTCTA	AGGAGTGGGTGTCGCTGT